Intra-Cellular Therapies Inc. (NASDAQ:ITCI) was down 2.8% on Thursday . The company traded as low as $39.49 and last traded at $39.52, with a volume of 216,727 shares changing hands. The stock had previously closed at $40.65.

A number of equities research analysts have weighed in on ITCI shares. Cowen and Company reaffirmed a “buy” rating and set a $75.00 price objective on shares of Intra-Cellular Therapies in a report on Friday, August 5th. Leerink Swann reaffirmed a “buy” rating on shares of Intra-Cellular Therapies in a report on Thursday, June 30th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $57.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, June 22nd. Finally, Zacks Investment Research downgraded Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Friday, April 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $70.78.

The company’s market capitalization is $1.72 billion. The firm has a 50-day moving average of $40.80 and a 200-day moving average of $35.16.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.08. The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.02 million. The business’s revenue was up 283.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.61) EPS. On average, equities analysts expect that Intra-Cellular Therapies Inc. will post ($3.17) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Intra-Cellular Therapies stock. Marshall Wace LLP increased its position in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 23.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,148 shares of the biopharmaceutical company’s stock after buying an additional 4,410 shares during the period. Marshall Wace LLP owned 0.05% of Intra-Cellular Therapies worth $1,245,000 at the end of the most recent reporting period.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.